Prescription drug abuse among female survivors of intimate partner violence: a call for research

Substance abuse, including the misuse of prescription drugs, has increased in the last two decades around the world (McCabe, et al., 2007; National Institute on Drug Abuse [NIDA], 2023; World Health Organisation [WHO], 2020). Global sources estimated that 5.5% of people aged 15-64 years worldwide ha...

Descripción completa

Detalles Bibliográficos
Autores: Haro Escribano, Begoña, Cuesta-García, Andrea, Miguel-Alvaro, Alejandro, Fernández-Montalvo, Javier, Crespo, María
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2023
País:España
Institución:Universidad Pública de Navarra
Repositorio:Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
OAI Identifier:oai:academica-e.unavarra.es:2454/45359
Acceso en línea:https://hdl.handle.net/2454/45359
Access Level:acceso abierto
Palabra clave:Prescription drug abuse
Intimate partner violence
female IPV survivors
id ES_35f71aa86bbb8db7ab5ca45fad5e8708
oai_identifier_str oai:academica-e.unavarra.es:2454/45359
network_acronym_str ES
network_name_str España
repository_id_str
spelling Prescription drug abuse among female survivors of intimate partner violence: a call for researchHaro Escribano, BegoñaCuesta-García, AndreaMiguel-Alvaro, AlejandroFernández-Montalvo, JavierCrespo, MaríaPrescription drug abuseIntimate partner violencefemale IPV survivorsSubstance abuse, including the misuse of prescription drugs, has increased in the last two decades around the world (McCabe, et al., 2007; National Institute on Drug Abuse [NIDA], 2023; World Health Organisation [WHO], 2020). Global sources estimated that 5.5% of people aged 15-64 years worldwide had used an illicit drug and that 0.7% of the adult population suffered from drug use disorders. A proportion of disorders is associated with the non-medical use of prescription drugs such as synthetic opioid analgesics, anxiolytics, hypnotics or psychostimulants (NIDA, 2023; WHO, 2020). Furthermore, prescription drug abuse (PDA) might be higher in specific populations such as women with substance use disorder (SUD; Peteet, 2020), especially among those who had attempted suicide (Icick, 2017). Some of the factors that have been related with PDA are histories of abuse and the lessened stigma associated with the use of prescription drugs compared to the use of illegal drugs (Fleary et al., 2013). For example, survivors of violence have presented a greater vulnerability to substance abuse (Khantzian, 1997), than has serious medical consequences (Benyamin et al., 2008). Intimate partner violence (IPV) is a global public health problem associated with several physical and mental health consequences in women such as depression, anxiety, or substance abuse (Campbell, 2002). Among these consequences, Bailey et al. (2019) indicated that women abused substances to manage their emotions. This relationship has been mostly supported by the self-medication hypothesis, which holds that people with an addiction problem seek to cope with emotional distress through substance use (Khantzian, 1997). Although the relationship between IPV and substance use has been established among women (Ahmadabadi et al., 2019; Golding, 1999), few studies have examined the specific relationship between IPV and PDA. In recent years, an increase in PDA among Spanish women who had suffered IPV has been observed (Ministerio de Igualdad, 2020). The most prevalent prescribed drugs were both anxiolytic and antidepressant drugs, with higher rates of use among IPV survivors than among the general population (Crespo et al., 2017). In other countries, studies found that almost half of participants were taking pain and/or psychotropic medications to cope with IPV impact (Wuest et al., 2007). On the other hand, victimization histories were more extensive among women who used sedative-hypnotics and opiates compared to women who did not (Kubiak et al., 2006). As IPV may be a predisposing factor for the development of PDA (Kubiak et al., 2006), the main goals of this review were to provide a summary of recent research on the relationship between IPV and PDA, identify gaps in knowledge and propose specific avenues for future research.Grants for the Requalification of the Spanish University System for 2021-2023, Universidad Pública de Navarra. Margarita Salas funded by the European Union – NextGenerationEU granted to B. Haro. Predoctoral grant by the Spanish Ministry of Universities (FPU19/01468) granted to A. Miguel-Alvaro.SpringerCiencias de la SaludOsasun ZientziakUniversidad Pública de Navarra / Nafarroako Unibertsitate Publikoa2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfapplication/mswordhttps://hdl.handle.net/2454/45359reponame:Academica-e. Repositorio Institucional de la Universidad Pública de Navarrainstname:Universidad Pública de NavarraInglésinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/FPU19%2F01468© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023info:eu-repo/semantics/openAccessoai:academica-e.unavarra.es:2454/453592026-06-17T12:41:47Z
dc.title.none.fl_str_mv Prescription drug abuse among female survivors of intimate partner violence: a call for research
title Prescription drug abuse among female survivors of intimate partner violence: a call for research
spellingShingle Prescription drug abuse among female survivors of intimate partner violence: a call for research
Haro Escribano, Begoña
Prescription drug abuse
Intimate partner violence
female IPV survivors
title_short Prescription drug abuse among female survivors of intimate partner violence: a call for research
title_full Prescription drug abuse among female survivors of intimate partner violence: a call for research
title_fullStr Prescription drug abuse among female survivors of intimate partner violence: a call for research
title_full_unstemmed Prescription drug abuse among female survivors of intimate partner violence: a call for research
title_sort Prescription drug abuse among female survivors of intimate partner violence: a call for research
dc.creator.none.fl_str_mv Haro Escribano, Begoña
Cuesta-García, Andrea
Miguel-Alvaro, Alejandro
Fernández-Montalvo, Javier
Crespo, María
author Haro Escribano, Begoña
author_facet Haro Escribano, Begoña
Cuesta-García, Andrea
Miguel-Alvaro, Alejandro
Fernández-Montalvo, Javier
Crespo, María
author_role author
author2 Cuesta-García, Andrea
Miguel-Alvaro, Alejandro
Fernández-Montalvo, Javier
Crespo, María
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Ciencias de la Salud
Osasun Zientziak
Universidad Pública de Navarra / Nafarroako Unibertsitate Publikoa
dc.subject.none.fl_str_mv Prescription drug abuse
Intimate partner violence
female IPV survivors
topic Prescription drug abuse
Intimate partner violence
female IPV survivors
description Substance abuse, including the misuse of prescription drugs, has increased in the last two decades around the world (McCabe, et al., 2007; National Institute on Drug Abuse [NIDA], 2023; World Health Organisation [WHO], 2020). Global sources estimated that 5.5% of people aged 15-64 years worldwide had used an illicit drug and that 0.7% of the adult population suffered from drug use disorders. A proportion of disorders is associated with the non-medical use of prescription drugs such as synthetic opioid analgesics, anxiolytics, hypnotics or psychostimulants (NIDA, 2023; WHO, 2020). Furthermore, prescription drug abuse (PDA) might be higher in specific populations such as women with substance use disorder (SUD; Peteet, 2020), especially among those who had attempted suicide (Icick, 2017). Some of the factors that have been related with PDA are histories of abuse and the lessened stigma associated with the use of prescription drugs compared to the use of illegal drugs (Fleary et al., 2013). For example, survivors of violence have presented a greater vulnerability to substance abuse (Khantzian, 1997), than has serious medical consequences (Benyamin et al., 2008). Intimate partner violence (IPV) is a global public health problem associated with several physical and mental health consequences in women such as depression, anxiety, or substance abuse (Campbell, 2002). Among these consequences, Bailey et al. (2019) indicated that women abused substances to manage their emotions. This relationship has been mostly supported by the self-medication hypothesis, which holds that people with an addiction problem seek to cope with emotional distress through substance use (Khantzian, 1997). Although the relationship between IPV and substance use has been established among women (Ahmadabadi et al., 2019; Golding, 1999), few studies have examined the specific relationship between IPV and PDA. In recent years, an increase in PDA among Spanish women who had suffered IPV has been observed (Ministerio de Igualdad, 2020). The most prevalent prescribed drugs were both anxiolytic and antidepressant drugs, with higher rates of use among IPV survivors than among the general population (Crespo et al., 2017). In other countries, studies found that almost half of participants were taking pain and/or psychotropic medications to cope with IPV impact (Wuest et al., 2007). On the other hand, victimization histories were more extensive among women who used sedative-hypnotics and opiates compared to women who did not (Kubiak et al., 2006). As IPV may be a predisposing factor for the development of PDA (Kubiak et al., 2006), the main goals of this review were to provide a summary of recent research on the relationship between IPV and PDA, identify gaps in knowledge and propose specific avenues for future research.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2454/45359
url https://hdl.handle.net/2454/45359
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/FPU19%2F01468
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/msword
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
instname:Universidad Pública de Navarra
instname_str Universidad Pública de Navarra
reponame_str Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
collection Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869405928363655168
score 15,300724

Similares en LA Referencia